Aethlon Medical (NASDAQ:AEMD) Earns Neutral Rating from HC Wainwright

Aethlon Medical (NASDAQ:AEMD)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright also issued estimates for Aethlon Medical’s Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.14) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.49) EPS, FY2029 earnings at ($0.49) EPS and FY2030 earnings at ($0.33) EPS.

Separately, Wall Street Zen began coverage on shares of Aethlon Medical in a research report on Thursday, May 15th. They set a “sell” rating on the stock.

Aethlon Medical Price Performance

Shares of AEMD opened at $1.14 on Thursday. The company has a market capitalization of $2.96 million, a P/E ratio of -0.09 and a beta of 1.72. Aethlon Medical has a one year low of $1.09 and a one year high of $8.44. The business’s 50 day simple moving average is $1.40 and its 200-day simple moving average is $2.84.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, August 13th. The medical equipment provider reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.17). On average, sell-side analysts anticipate that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Aethlon Medical

A number of large investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new position in shares of Aethlon Medical during the first quarter worth approximately $511,000. Boothbay Fund Management LLC bought a new stake in shares of Aethlon Medical during the fourth quarter worth approximately $186,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Aethlon Medical during the fourth quarter worth approximately $31,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Aethlon Medical during the fourth quarter worth approximately $25,000. 1.99% of the stock is currently owned by institutional investors and hedge funds.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.